Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer

This cohort study examines patterns of bone-modifying agent use from 2013 to 2024 among men with metastatic castration-resistant prostate cancer.

Corresponding Authors: Neeraj Agarwal, MD (neeraj.agarwal@hci.utah.edu), and Umang Swami, MD, MS (umang.swami@hci.utah.edu), Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Suite 5510, Salt Lake City, UT 84112.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.